Takeda Pharmaceutical (NYSE:TAK - Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 3.060-3.060 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.
Takeda Pharmaceutical Stock Performance
Shares of NYSE:TAK traded up $0.06 on Thursday, reaching $13.95. 1,312,149 shares of the company's stock were exchanged, compared to its average volume of 1,850,965. The firm has a market capitalization of $44.39 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 0.26 and a beta of 0.54. Takeda Pharmaceutical has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The business's 50-day moving average is $14.50 and its two-hundred day moving average is $13.78. The company has a quick ratio of 0.74, a current ratio of 1.26 and a debt-to-equity ratio of 0.65.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. As a group, equities research analysts forecast that Takeda Pharmaceutical will post 1.58 EPS for the current year.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
